9th Mar 2016 10:27
LONDON (Alliance News) - ImmuPharma PLC said Wednesday it has begun patient recruitment in Europe in its phase III clinical trial of Lupuzor for auto immune disease Lupus.
The company has opened its first European site in Bordeaux, France, to begin recruitment. This follows the first US patients beginning dosing last month.
"Following the initial US sites being opened and the first Lupus patients having commenced dosing we are delighted that we have hit another key milestone with patient recruitment started in our first European site in France. We look forward to providing further positive updates on this Lupuzor Phase III study as it progresses throughout this year and 2017," said Chairman Tim McCarthy in a statement.
Shares in ImmuPharma were untraded Wednesday morning. They last closed at 26.10 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma